With a CAGR of 6.7%, the immune repertoire sequencing market will hit
Brooklyn, New York, June 24, 2022 (GLOBE NEWSWIRE) — Reports and Insights has just added a report titled “Immune Repertoire Sequencing Market: Analysis of opportunities and future assessment 2022-2030in its database of market research reports which offers its readers a detailed and in-depth analysis of new growth opportunities, trends and growth drivers closely related to market growth. The report further provides crucial insights regarding the impacts of COVID-19 on the Immune Repertoire Sequencing market along with the Compound Growth Rate (CAGR) of the market for an anticipated period between 2022 and 2030. According to research by Reports and Insights, the immune system repertoire sequencing market is estimated to reach a value of US$111.0 million by the end of 2022 and should reach to a worth US$186.9 million by 2030 with a significant CAGR of 6.7%. The report also includes an assessment of the market using various analytical tools, such as Porter’s Five Forces analysis and PESTEL analysis. These tools also offer in-depth analysis of micro and macro-environmental factors related to market growth over the projected period.
Get a sample full PDF copy of the report with table of contents: https://reportsandinsights.com/sample-request/4123
Introduction to immune repertoire sequencing
Immune repertoire sequencing has helped profile antigen-specific information in lymphocytes and has been shown to be essential in understanding the body’s mechanism of self-defense against foreign agents. Importantly, immune repertoire sequencing has proven to be an extremely useful tool for quantifying the configuration of B or T cell antigen receptor repertoires in basic research, such as immune repertoire development, vaccination, and lymphocyte lineage monitoring, as well as in several different clinical settings, such as monitoring hematopoietic stem cell transplant recovery, monitoring minimal residual disease (MRD), and prognosis of cancer patients. That said, early IR-seq experiments observed high PCR and sequencing errors that limited their ability to perform foolproof quantification of repertoire diversity and abundance.
Key insights from market research
- The immune repertoire sequencing market is expected to reach a value of US$111.0M by the end of 2022 and is expected to reach a value of US$186.9M by 2030 with a significant CAGR of 6.7%
- The test kits product segment in the immune repertoire sequencing market is expected to create an additional opportunity of US$25.6 million during the forecast period
- In 2022, the cancer immunotherapy applications segment accounted for the largest market share and is expected to grow at 7.9% CAGR during the forecast period.
- In 2022, the end-user segment of diagnostic laboratories accounted for the largest market share
- Asia-Pacific is expected to remain the leading region in the global market and is expected to remain the fastest growing region
- U.S. Immune Repertoire Sequencing Market Expected to Grow 1.8x during the forecast period
See the latest updates and developments in the Global Immune Repertoire Sequencing Market – https://reportsandinsights.com/pressrelease/immune-repertoire-sequencing-market
Immune Repertoire Sequencing Market Dynamics
Booming use of IR-seq in cancer immunotherapy
Cancer, being the leading cause of death globally, recently accounted for around 10 million deaths in 2020, or almost one in six deaths. Cancer usually arises from the transfiguration of normal cells into tumor cells in a multilevel process that usually develops from a precancerous lesion to a malignant tumor. Moreover, cancer treatment is again and again steeped in complexities. The disease’s unconstrained and pernicious cell growth is largely the result of erratic mutations in the body. Moreover, mutations persist as the disease progresses, producing heterogeneous tumors in which some tumor cells are likely to be unaffected by the treatment regimen. At the same time, the diversity of the immune repertoire is a robust indicator of disease status and response. In other words, sequencing of the immune repertoire can be seen as a robust instrument for assessing the immune repertoire, as it has the potential to qualitatively and quantitatively measure the diversity of the immune system. There are numerous cases in the literature in which the diversity of the immune repertoire has been linked to the presence or development of disease in cancer.
Recently, researchers from the Chinese Academy of Medical Sciences demonstrated that TCR-gamma CDR3 diversity is significantly reduced in patients with lung cancer. Similarly, patients with renal cell cancer show reduced repertoire diversity compared to normal controls. In another case, the collation of immune repertoires from pediatric and adult patients with acute myeloid leukemia revealed that clonal expansion of B and T cells occurs in diseased patients. Collectively, these results suggest that the representation of the immune repertoire has the ability to offer a robust diagnostic tool in the analysis of cancer. Immune cell repertoires can be assessed in certain cancers to better understand how the immune system changes during progression or remission. Finally, these representations are likely to even help suggest to clinicians the best treatment alternatives.
View report details before purchase – https://reportsandinsights.com/report/immune-repertoire-sequencing-market
Immune Repertoire Sequencing Market Segmentation
The global immune repertoire sequencing market is segmented on the basis of product, topic type, application, end-user and region
TCR Analysis Solutions
BCR Analysis Solutions
TCR and BCR analysis solutions
Data Analysis Services
By subject type
Drug retrieval based on pharmacogenomics
Next Generation Sequencing
Polymerase chain reaction
Discovery of biomarkers
Infectious Disease Research
Asthma and Allergy Research
Identification of immunodeficiency
Per end user
Pharmaceutical and biotechnology companies
Immune Repertoire Sequencing Market Key Players
Some of the Major Participating Players in the Global Immune Repertoire Sequencing Market are:
Pacific Biosciences of California, Inc.
Agilent Technologies, Inc.
Oxford Nanopore Technologies, Ltd.
Thermo Fisher Scientific
F. Hoffmann-La Roche SA
Takara Bio, Inc.
To view top players, segmentation and other statistics of Immune repertoire sequencing Industry, get a sample report: @ https://reportsandinsights.com/sample-request/4123
About reports and insights:
Reports and Insights is a leading market research company that offers group and consulting research worldwide. At Reports and Insights, we adhere to client needs and reflect regularly to bring out more valuable and real results for our clients. We are equipped with a strategically strengthened group of researchers and analysts who redefine and stabilize trade polarity in different categorical dimensions of the market.